Medical cannabis and cannabinoids in rheumatology: where are we now?

References

• D’souza DC, Ranganathan M. Medical marijuana: is the cart before the horse? JAMA. 2015;313:2431–2432.
   PubMed Web of Science ®Google Scholar
• Katz-Talmor D, Katz I, Porat-Katz BS, et al. Cannabinoids for the treatment of rheumatic diseases - where do we stand? Nat Rev Rheumatol. 2018 Aug;14(8):488–498.
   PubMed Web of Science ®Google Scholar
• Vučković S, Srebro D, Vujović KS, et al. Cannabinoids and pain: new insights from old molecules. Front Pharmacol. 2018 Nov;13(9):1259.
   Google Scholar
• Fraguas-Sánchez AI, Torres-Suárez AI. Medical use of cannabinoids. Drugs. 2018 Nov;78(16):1665–1703.
   PubMed Web of Science ®Google Scholar
• Krcevski-Skvarc N, Wells C, Hauser W. Availability And Approval Of Cannabis-Based Medicines For Chronic Pain Management And Palliative/Supportive Care In Europe: a survey of the status in the chapters of the European pain federation. Eur J Pain. 2018 Mar;22(3):440–454.
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Hanu S. Historical overview of chemical research on cannabinoids. Chem Phys Lipids. 2000 Nov;108(1–2):1–13.
   PubMed Web of Science ®Google Scholar
• Hanus L, Abu-Lafi S, Fride E, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid Cb1 receptor. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3662–3665.
   PubMed Web of Science ®Google Scholar
• Oka S, Tsuchie A, Tokumura A, et al. Ether-linked analogue of 2-arachidonoylglycerol (Noladin Ether) was not detected in the brains of various mammalian species. J Neurochem. 2003 Jun;85(6):1374–1381.
   PubMed Web of Science ®Google Scholar
• Reggio PH. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains. Curr Med Chem. 2010;17(14):1468–1486.
   PubMed Web of Science ®Google Scholar
• Glass M, Dragunow M, Faull R. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997 Mar;77(2):299–318.
   PubMed Web of Science ®Google Scholar
• Westlake TM, Howlett AC, Bonner TI, et al. Cannabinoid receptor binding and messenger rna expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience. 1994 Dec;63(3):637–652.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Pharmacology of cannabinoid Cb1 And Cb2 receptors. Pharmacol Ther. 1997;74(2):129–180.
   PubMed Web of Science ®Google Scholar
• Gerard C, Mollereau C, Vassart G, et al. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J. 1991 Oct 1;279(Pt 1):129–134.
   PubMedGoogle Scholar
• Straiker A, Maguire G, Mackie K, et al. Localization of cannabinoid cb1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2442–2448.
   PubMed Web of Science ®Google Scholar
• Schuel H, Chang MC, Burkman LJ, et al. Cannabinoid receptors in sperm. In: Nahas GG, Sutin KM, Harvey D, Agurell S, Pace N, Cancro R, editors. Marijuana and medicine. Totowa, NJ: Humana press; 1999. p. 335–345.
   Google Scholar
• Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology. 2005 Aug;129(2):437–453.
   PubMed Web of Science ®Google Scholar
• Roche R, Hoareau L, Bes-Houtmann S, et al. Presence of the cannabinoid receptors, Cb1 And Cb2, in human omental and subcutaneous adipocytes. Histochem Cell Biol. 2006 Aug;126(2):177–187. Epub 2006 Jan 4.
   PubMed Web of Science ®Google Scholar
• Bouaboula M, Rinaldi M, Carayon P, et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem. 1993 May 15;214(1):173–180.
   PubMedGoogle Scholar
• Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995 Aug 15;232(1):54–61.
   PubMedGoogle Scholar
• Rice W, Shannon JM, Burton F, et al. Expression of a brain-type cannabinoid receptor (Cb1) in alveolar type ii cells in the lung: regulation by hydrocortisone. Eur J Pharmacol. 1997 May 30;327(2–3):227–232.
   PubMed Web of Science ®Google Scholar
• Gui H, Tong Q, Qu W, et al. The endocannabinoid system and its therapeutic implications in rheumatoid arthritis. Int Immunopharmacol. 2015 May;26(1):86–91.
   PubMed Web of Science ®Google Scholar
• Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid Cb1 and Cb2 receptors. Mol Pharmacol. 1995 Sep;48(3):443–450.
   PubMed Web of Science ®Google Scholar
• Bellini G, Olivieri AN, Grandone A, et al. Association between cannabinoid receptor type 2 Q63r variant and oligo/polyarticular juvenile idiopathic arthritis. Scand J Rheumatol. 2015;44(4):284–287.
   PubMed Web of Science ®Google Scholar
• Pertwee RG, Howlett AC, Abood ME, et al. Cannabinoid receptors and their ligands: beyond Cb1 and Cb2. Pharmacol Rev. 2010 Dec;62(4):588–631.
   PubMed Web of Science ®Google Scholar
• Baker C, Mcdougall JI. The cannabinomimetic arachidonyl-2-chloroethylamide (acea) acts on capsaicin-sensitive trpv1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol. 2004 Aug;142(8):1361–1367.
   PubMed Web of Science ®Google Scholar
• O’Sullivan SE. An update on ppar activation by cannabinoids. Br J Pharmacol. 2016 Jun;173(12):1899–1910.
   PubMed Web of Science ®Google Scholar
• Aggarwal SK, Carter GT, Sullivan MD, et al. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009;5(3):153–168.
   PubMedGoogle Scholar
• Andre CM, Hausman JF, Guerriero G. Cannabis sativa: the plant of the thousand and one. Front Plant Sci. 2016 Feb;4(7):19.
   Google Scholar
• Reekie TA, Scott MP, Kassiou M. The evolving science of phytocannabinoids. Nat Rev Chem. 2017 Dec;2:0101.
   Web of Science ®Google Scholar
• Russo EB. Taming THC potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011 Aug;163(7):1344–1364.
   PubMed Web of Science ®Google Scholar
• Sanchez Robles EM, Bagues Arias A, Martin Fontelles MI. Cannabinoids and muscular pain. effectiveness of the local administration in rat. Eur J Pain. 2012 Sep;16(8):1116–1127.
   PubMed Web of Science ®Google Scholar
• Schuelert N, Mcdougall JI. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis Rheum. 2008 Jan;58(1):145–153.
   PubMedGoogle Scholar
• Häuser W, Petzke F. Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - an overview of systematic reviews. Eur J Pain. 2018 Mar;22(3):455–470.
   PubMed Web of Science ®Google Scholar
• Mücke M, Phillips T, Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018 Mar 7;3:CD012182. doi: 10.1002/14651858.CD012182.pub2.
   Google Scholar
• Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of fda-approved products of oral solutions containing dronabinol [(-)-delta-9-trans- tetrahydrocannabinol (delta-9-THC)] in schedule II. Final rule. Fed Regist. 2017 Nov 22;82(224):55504–55506.
   PubMedGoogle Scholar
• Russell C, Rueda S, Room R, et al. Routes of administration for cannabis use - basic prevalence and related health outcomes: a scoping review and synthesis. Int J Drug Policy. 2018 Feb;52:87–96.
   PubMed Web of Science ®Google Scholar
• Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: a systematic review. Autoimmun Rev. 2016 Jun;15(6):513–528.
   PubMed Web of Science ®Google Scholar
• Bruni N, Della Pepa C, Oliaro-Bosso S, et al. Cannabinoid delivery systems for pain and inflammation treatment. Molecules. 2018 Sep 27;23:10.
   Web of Science ®Google Scholar
• Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016 Jul;20(6):936–948.
   PubMed Web of Science ®Google Scholar
• MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–19.
   Google Scholar
• Ablin J, Ste-Marie PA, Schäfer M, et al. Medical use of cannabis products: lessons to be learned from Israel and Canada. Schmerz. 2016 Feb;30(1):3–13.
   PubMed Web of Science ®Google Scholar
• Andreae MH, Carter GM, Shaparin N, et al. cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain. 2015 Dec;16(12):1221–1232.
   PubMed Web of Science ®Google Scholar
• Shapira Y, Agmon–Levin N, Shoenfeld Y. Geoepidemiology Of Autoimmune Rheumatic Diseases. Nat Rev Rheumatol. 2010 Aug;6(8):468–476.
   PubMed Web of Science ®Google Scholar
• Sumariwalla P, Gallily R, Tchilibon S, et al. A novel synthetic, nonpsychoactive cannabinoid acid (Hu-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 2004 Mar;50(3):985–998.
   PubMedGoogle Scholar
• Zurier RB, Rossetti RG, Lane JH, et al. Dimethylheptyl-thc-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum. 1998 Jan;41(1):163–170.
   PubMedGoogle Scholar
• Selvi E, Lorenzini S, Garcia-Gonzalez E, et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin Exp Rheumatol. 2008 Jul-Aug;26(4):574–581.
   PubMed Web of Science ®Google Scholar
• Katz D, Katz I, Porat-Katz BS, et al. Medical cannabis: another piece in the mosaic of autoimmunity? Clin Pharmacol Ther. 2017 Feb;101(2):230–238.
   PubMed Web of Science ®Google Scholar
• Johnson DR, Stebulis JA, Rossetti RG, et al. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J Cell Biochem. 2007 Jan 1;100(1):184-190.
   PubMed Web of Science ®Google Scholar
• Richardson D, Pearson RG, Kurian N, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008 Apr;10:(2):R43.
   Web of Science ®Google Scholar
• Lowin T, Pongratz G, Straub RH. The synthetic cannabinoid win55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating Cb2, Trpv1, Trpa1 and yet unidentified receptor targets. J Inflamm (Lond). 2016 May 5;13:15.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Kohsaka H, Takayasu A, et al. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskelet Disord. 2014 Aug 12;15:275.
   PubMed Web of Science ®Google Scholar
• Malfait A, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti- arthritic therapeutic in murine collagen- induced arthritis. Proc Proc Natl Acad Sci USA. 2000 Aug 15;97(17):9561–9566.
   PubMed Web of Science ®Google Scholar
• Gui H, Liu X, Liu LR, et al. Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen- induced arthritis. Immunobiology. 2015 Jun;220(6):817–822.
   PubMed Web of Science ®Google Scholar
• Blake D, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine sativex in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006 Jan;45(1):50–52.
   PubMed Web of Science ®Google Scholar
• Bannuru RR, Schimd CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis. Intern Med. 2015 Jan 6;162(1):46–54.
   Web of Science ®Google Scholar
• Kong Y, Wang W, Zhang C, et al. Cannabinoid win-55,212–2 mesylate inhibits adamts-4 activity in human osteoarthritic articular chondrocytes by inhibiting expression of syndecan-1. Mol Med Rep. 2016 Jun;13(6):4569–4576.
   PubMed Web of Science ®Google Scholar
• Ste-Marie PA, Shir Y, Rampakakis W, et al. Survey of herbal cannabis (Marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis. Pain. 2016 Dec;157(12):2792–2797.
   PubMed Web of Science ®Google Scholar
• Sophocleous A, Börjesson AE, Salter DM, et al. The type 2 cannabinoid receptor regulates susceptibility to osteoarthritis in mice. Osteoarthritis Cartilage. 2015 Sep;23(9):1586–1594.
   PubMed Web of Science ®Google Scholar
• Mbvundula EC, Bunning RAD, Rainsford KD. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem Pharmacol. 2005 Feb 15;69(4):635–640.
   PubMed Web of Science ®Google Scholar
• Gòmez R, Conde J, Scotece M, et al. Endogenous cannabinoid anandamide impairs cell growth and induces apoptosis in chondrocytes. J Orthop Res. 2014 Sep;32(9):1137–1146.
   PubMed Web of Science ®Google Scholar
• Larosa M, Iaccarino L, Gatto M, et al. Advances in the diagnosis and classification of systemic lupus erythematosus. Expert Rev Clin Immunol. 2016 Dec;12(12):1309–1320.
   PubMed Web of Science ®Google Scholar
• Tsokos G, Lo M, Reis P, et al. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016 Nov 22;12(12):716–730.
   PubMed Web of Science ®Google Scholar
• Chiurchiù V, Battistini L, Maccarrone M. Endocannabinoid signalling in innate and adaptive immunity. Immunology. 2015 Mar;144(3):352–364.
   PubMed Web of Science ®Google Scholar
• Navarini L, Bisogno T, Mozetic P, et al. Endocannabinoid system in systemic lupus erythematosus: first evidence for a deranged 2-arachidonoylglycerol metabolism. Int J Biochem Cell Biol. 2018 Apr;99:161–168.
   PubMed Web of Science ®Google Scholar
• Parker J, Atez F, Rossetti RG, et al. Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatol Int. 2008 May;28(7):631–635.
   PubMed Web of Science ®Google Scholar
• Grossman C, Dovrish Z, Shoenfeld Y, et al. Do infections facilitate the emergence of systemic sclerosis? Autoimmun Rev. 2011 Mar;10(5):244–247.
   PubMed Web of Science ®Google Scholar
• Rossi D, Zanatta E, Marson P, et al. How i treat patients with systemic sclerosis in clinical practice. Autoimmun Rev. 2017 Oct;16(10):1024–1028.
   PubMed Web of Science ®Google Scholar
• Marquart S, Zerr P, Akhmetshina A, et al. Inactivation of the cannabinoid receptor cb1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum. 2010 Nov;62(11):3467–3476.
   PubMedGoogle Scholar
• Akhmetshina A, Dees C, Busch N, et al. The cannabinoid receptor Cb2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum. 2009 Apr;60(4):1129–1136.
   PubMed Web of Science ®Google Scholar
• Del Río C, Navarrete C, Collado JA, et al. The cannabinoid quinol vce-004.8 alleviates bleomycin- induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator- activated receptor- γ and Cb2 Pathways. Sci Rep. 2016 Feb 18; 6:21703.
   PubMed Web of Science ®Google Scholar
• Servettaz A, Kavian N, Nicco C, et al. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol. 2010 Jul;177(1):187–196.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhao R, Li JY, et al. Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing. Eur J Pharmacol. 2016 Sep 5;786:128–136.
   PubMed Web of Science ®Google Scholar
• Li S, Wang L, Liu M, et al. Cannabinoid cb2 receptors are involved in the regulation of fibrogenesis during skin wound repair in mice. Mol Med Rep. 2016 Apr;13(4):3441–3450.
   PubMed Web of Science ®Google Scholar
• Garcia- Gonzalez E, Selvi E, Balistreri E, et al. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology (Oxford). 2009 Sep;48(9):1050–1056.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw D, Fitzcharles M, et al. 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016 Dec;46(3):319–329.
   PubMed Web of Science ®Google Scholar
• Mcbeth J, Tomenson B, Chew-Graham CA, et al. Common and unique associated factors for medically unexplained chronic widespread pain and chronic fatigue. J Psychosom Res. 2015 Dec;79(6):484–491.
   PubMed Web of Science ®Google Scholar
• Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015 Jun 23-30;313(24):2474–2478.
   PubMed Web of Science ®Google Scholar
• Clarke R, Merlin M. Introduction to the multipurpose plant cannabis. cannabis: evolution and ethnobotany. Berkeley, Ca: University Of California Press; 2013. p. 1–24.
   Google Scholar
• Fitzcharles MA, Jamal S. Expanding medical marijuana access in canada: considerations for the rheumatologist. J Rheumatol. 2015 Feb;42(2):143–145.
   PubMed Web of Science ®Google Scholar
• Walsh Z, Callaway R, Belle-Isle L, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013 Nov;24(6):511–516.
   PubMed Web of Science ®Google Scholar
• Ware M, Adams H, Guy GW, et al. The medicinal use of cannabis in the uk: results of a nationwide survey. Int J Clin Pract. 2005 Mar;59(3):291–295.
   PubMed Web of Science ®Google Scholar
• Aggarwal SK, Carter GT, Sullivan MD, et al. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington state. J Opioid Manag. 2009 Sep–Oct;5(5):257–286.
   PubMedGoogle Scholar
• Walitt B, Klose P, Fitzcharles M, et al. Cannabinoids For Fibromyalgia. Cochrane Database Syst Rev. 2016 Jul;18;7.
   Google Scholar
• Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008 9(2):164–173. Epub 2007 Nov 5.
   PubMed Web of Science ®Google Scholar
• Ware M, Fitzcharles MA, Joseph L, et al. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010 Feb 1;110(2):604–610.
   PubMed Web of Science ®Google Scholar
• The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington (DC): National Academies Press (US); 2017 Jan.
   Google Scholar
• Fiz J, Durán M, Capellà D, et al. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health- related quality of life. PLoS One. 2011 Apr 21;6(4).
   PubMed Web of Science ®Google Scholar
• Van De Donk T, Niesters M, Kowal MA, et al. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019 Apr;160(4):860–869.
   PubMed Web of Science ®Google Scholar
• Yassin M, Oron A, Robinson D. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. Clin Exp Rheumatol. 2019;37 Suppl 116(1): 13–20. Jan-Feb.
   PubMed Web of Science ®Google Scholar
• Fitzcharles MA, Baerwald C, Ablin J, et al. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz. 2016 Feb;30(1):47–61.
   PubMed Web of Science ®Google Scholar
• Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178:1669–1678.
   PubMed Web of Science ®Google Scholar
• Callaghan RC, Allebeck P, Akre O, et al. Cannabis Use and Incidence of Testicular Cancer: A 42-Year Follow-up of Swedish Men between 1970 and 2011. Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1644–1652.
   PubMed Web of Science ®Google Scholar
• Merlob P, Stahl B, Klinger G. For debate: does cannabis use by the pregnant mother affect the fetus and newborn? Pediatr Endocrinol Rev. 2017 Sep;15(1):4–7.
   PubMed Web of Science ®Google Scholar
• Grant K, Petroff R, Isoherranen N, et al. Cannabis use during pregnancy: pharmacokinetics and effects on child development. Pharmacol Ther. 2018 Feb;182:133–151.
   PubMed Web of Science ®Google Scholar
• The American College of Obstetricians and Gynecologists. Committee on obstetric practice. 2017. p. 722.
   Google Scholar
• Wong SS, Wilens TE. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics. 2017 Nov;140:5.
   Web of Science ®Google Scholar
• Camchong J, Lim KO, Kumra S. Adverse effects of cannabis on adolescent brain development: a longitudinal study. Cereb Cortex. 2017 Mar 1;27(3):1922–1930.
   PubMed Web of Science ®Google Scholar
• Levine A, Clemenza K, Rynn M. Evidence for the risks and consequences of adolescent cannabis exposure. J Am Acad Child Adolesc Psychiatry. 2017 Mar;56(3):214–225.
   PubMed Web of Science ®Google Scholar
• Fitzcharles MA, Ste-Marie PA, Clauw DJ, et al. Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints. BMC Musculoskelet Disord. 2014 Jul;30(15):258.
   Google Scholar
• Allan GM, Ramji J, Perry D, et al. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician. 2018 Feb;64(2):111–120.
   PubMed Web of Science ®Google Scholar
• Marconi A, Di Forti M, Lewis CM, et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016 Sep;42(5):1262–1269.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015 Jun 23-30;313(24):2456–2473.
   PubMed Web of Science ®Google Scholar
• Gibbs M, Winsper C, Marwaha S, et al. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015 Jan;15(171):39–47.
   Google Scholar
• Lev-Ran S, Roerecke M, Le Foll B, et al. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014 Mar;44(4):797–810.
   PubMed Web of Science ®Google Scholar
• Kedzior KK. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population–a meta-analysis of 31 studies. BMC Psychiatry. 2014 May 10;14:136.
   PubMed Web of Science ®Google Scholar
• Tashkin DP. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis. 2005 Jun;63(2):93–100.
   PubMedGoogle Scholar
• Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008 Jun 17;178(13):1669–1678.
   PubMed Web of Science ®Google Scholar
• Allan GM, Finley CR, Ton J, et al. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018 Feb;64(2):78–94.
   PubMed Web of Science ®Google Scholar
• Hall W, Degenhardt L. Cannabis use and the risk of developing a psychotic disorder. World Psychiatry. 2008;7(2):68–71.
   PubMed Web of Science ®Google Scholar
• Shukla PC, Moore UB. Marijuana-induced transient global amnesia. South Med J. 2004 Aug;97(8):782–784.
   PubMed Web of Science ®Google Scholar
• Battistella G, Fornari E, Annoni JM, et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology. 2014 Aug;39(9):2041–2048.
   PubMed Web of Science ®Google Scholar
• Hall W, Degenhardt L. High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis. BMJ. 2015 Mar;4(350):1205.
   Google Scholar
• Moreira FA, Grieb M, Lutz B, et al. Central side-effects of therapies based on Cb1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133–144.
   PubMed Web of Science ®Google Scholar
• Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657–64.
   PubMed Web of Science ®Google Scholar
• Park F, Potukuchi PK, Moradi H, et al. Cannabinoids and the kidney: effects in health and disease. Am J Physiol Renal Physiol. 2017 Nov 1;313(5):F1124–F1132.
   PubMed Web of Science ®Google Scholar
• Grant I, Cahn BR. Cannabis and endocannabinoid modulators: therapeutic promises and challenges. Clin Neurosci Res. 2005;5(2–4):185–199.
   PubMedGoogle Scholar
• Mayoral M, Calderón H, Cano R, et al. Allergic rhinoconjunctivitis caused by cannabis sativa pollen. J Investig Allergol Clin Immunol. 2008;18(1):73–74.
   PubMed Web of Science ®Google Scholar
• Richardson KA, Hester AK, McLemore GL. Prenatal cannabis exposure - The “first hit” to the endocannabinoid system. Neurotoxicol Teratol. 2016;58:5–14.
   PubMed Web of Science ®Google Scholar
• Hembree WC, Nahas GG, Zeidenberg P, et al. Changes in human spermatozoa associated with high-dose marihuana smoking. Adv Biosci. 1978 Jul;22-23:429–439.
   PubMedGoogle Scholar